We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $866M
1-Year Est. Return 231.68%
This Fund
S&P 500
This Quarter Est. Return
+48.07%
1 Year Est. Return
+231.68%
3 Year Est. Return
+883.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$866M
AUM Growth
+$233M
Cap. Flow
+$9.94M
Cap. Flow %
1.15%
Top 10 Hldgs %
98.82%
Holding
29
New
6
Increased
6
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
GHRS icon
GH Research
GHRS
+$52.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$24.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$2.19M
4
CCCC icon
C4 Therapeutics
CCCC
+$1.12M
5
TRAW icon
Traws Pharma
TRAW
+$750K

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$38.4M
2
STOK icon
Stoke Therapeutics
STOK
+$23.3M
3
XNCR icon
Xencor
XNCR
+$6.47M
4
IMTX icon
Immatics
IMTX
+$2.05M
5
DSGN icon
Design Therapeutics
DSGN
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$1.98B
$357M 41.19%
13,263,288
+2,500,000
+23% +$52.2M
CGEM icon
2
Cullinan Oncology
CGEM
$1.38B
$163M 18.86%
8,963,500
– –
STOK icon
3
Stoke Therapeutics
STOK
$1.87B
$132M 15.27%
4,038,404
-725,269
-15% -$23.3M
AGIO icon
4
Agios Pharmaceuticals
AGIO
$2.03B
$127M 14.62%
3,408,937
+797,369
+31% +$24.2M
CCCC icon
5
C4 Therapeutics
CCCC
$426M
$34.2M 3.95%
7,326,691
+327,789
+5% +$1.12M
KRRO icon
6
Korro Bio
KRRO
$201M
$20.3M 2.34%
1,538,296
– –
TCRX icon
7
TScan Therapeutics
TCRX
$24.4M
$7.86M 0.91%
8,019,148
– –
DTIL icon
8
Precision BioSciences
DTIL
$183M
$7.47M 0.86%
950,466
-34,647
-4% -$244K
NEUP
9
Neuphoria Therapeutics
NEUP
$20.2M
$3.83M 0.44%
875,328
– –
PASG icon
10
Passage Bio
PASG
$15.3M
$3.29M 0.38%
673,759
+50,055
+8% +$313K
CGON icon
11
CG Oncology
CGON
$6.7B
$2.23M 0.26%
31,391
-200
-0.6% -$13.1K
PLRX icon
12
Pliant Therapeutics
PLRX
$68.7M
$2.05M 0.24%
+1,798,070
New +$2.19M
TRDA icon
13
Entrada Therapeutics
TRDA
$268M
$1.31M 0.15%
178,606
-33,083
-16% -$317K
YARW
14
Yarrow Bioscience
YARW
$76.6M
$1.06M 0.12%
32,574
– –
PRQR icon
15
ProQR Therapeutics
PRQR
$265M
$970K 0.11%
521,413
+452,927
+661% +$746K
TRAW icon
16
Traws Pharma
TRAW
$8.08M
$472K 0.05%
559,470
+544,392
+3,611% +$750K
FHTX icon
17
Foghorn Therapeutics
FHTX
$249M
$301K 0.03%
+61,588
New +$273K
DNLI icon
18
Denali Therapeutics
DNLI
$3.26B
$300K 0.03%
11,658
-1,868,645
-99% -$38.4M
XNCR icon
19
Xencor
XNCR
$1.82B
$293K 0.03%
18,194
-518,204
-97% -$6.47M
ABSI icon
20
Absci
ABSI
$1.61B
$246K 0.03%
21,245
– –
HOWL icon
21
Werewolf Therapeutics
HOWL
$46.7M
$237K 0.03%
657,786
– –
IMTX icon
22
Immatics
IMTX
$1.36B
$235K 0.03%
23,236
-193,737
-89% -$2.05M
AVTX icon
23
Avalo Therapeutics
AVTX
$903M
$187K 0.02%
+10,100
New +$160K
BOLT icon
24
Bolt Biotherapeutics
BOLT
$6.63M
$119K 0.01%
30,800
– –
NUVB icon
25
Nuvation Bio
NUVB
$2.13B
$91K 0.01%
+16,029
New +$78.3K
1
2

Similar funds

LA
LexAurum Advisors Overland Park, Kansas $866M AUM
PWM
Parkway Wealth Management Plano, Texas $866M AUM
LA
LM Advisors San Diego, California $866M AUM 26.16% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $864M AUM 906.77% 1-Year Est. Return
BBI
Baxter Bros Inc Riverside, Connecticut $864M AUM 15.83% 1-Year Est. Return
FTF
Freedom Together Foundation New York $867M AUM 20.05% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
DOA
D'Orazio & Associates Falls Church, Virginia $864M AUM 21.64% 1-Year Est. Return

Lynx1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Lynx1 Capital Management held 29 positions worth $866M, up 37% from $633M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Lynx1 Capital Management's Q2 2026 filing shows 6 new, 6 increased, 7 reduced and 2 closed positions. Its largest new stake was Pliant Therapeutics: 1,798,070 shares worth $2.05M. The largest sale was Denali Therapeutics, an estimated $38.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management's largest Q2 2026 buy was Pliant Therapeutics: 1,798,070 shares worth $2.05M.
  • Lynx1 Capital Management added most to GH Research in Q2 2026, an estimated $52.2M increase.
  • Lynx1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $38.4M.
  • Lynx1 Capital Management fully exited Design Therapeutics in Q2 2026, selling an estimated $1.27M.
  • Lynx1 Capital Management's ten largest holdings make up 99% of its $866M portfolio in Q2 2026.
  • Lynx1 Capital Management opened 6 new positions and closed 2 in Q2 2026.
  • Lynx1 Capital Management's portfolio value rose 37% quarter-over-quarter to $866M.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.